Effect of Anthocyanins Extracted From Purple Potatoes on Healthy Study Subjects' Postprandial Glycemia and Insulinemia

Sponsor

University of Turku (Other)

Overall Status

Completed

CT.gov ID

NCT02940080

Collaborator

(none)

Enrollment

Location

Arms

Duration (Months)

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A randomized, single-blind cross-over clinical nutrition trial will be conducted. The effects of yellow-fleshed potatoes and yellow-fleshed potatoes supplemented with anthocyanins extracted from purple-fleshed potatoes on healthy men's postprandial glycemia and insulinemia will be compared. Additionally, the postprandial metabolism and metabolites, and the appearance and metabolism of the flavonoids and their metabolites is studied in plasma, urine and feces.

Condition or Disease	Intervention/Treatment	Phase
Postprandial Glycemia	Other: Dietary	N/A

Study Design

Study Type:

Interventional

Actual Enrollment :

18 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Single (Investigator)

Primary Purpose:

Basic Science

Official Title:

Effect of Anthocyanins Extracted From Purple Potatoes on Healthy Study Subjects' Postprandial Glycemia and Insulinemia

Study Start Date :

Oct 1, 2016

Actual Primary Completion Date :

Dec 31, 2021

Actual Study Completion Date :

Dec 31, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Anthocyanins and yellow potato 168 mg of anthocyanins extracted from purple-fleshed potatoes added to 350 g of steam-cooked mashed potatoes in water	Other: Dietary
Experimental: Yellow potato 350 g of steam-cooked mashed potatoes in water	Other: Dietary

Arm

Intervention/Treatment

Experimental: Anthocyanins and yellow potato

168 mg of anthocyanins extracted from purple-fleshed potatoes added to 350 g of steam-cooked mashed potatoes in water

Other: Dietary

Experimental: Yellow potato

350 g of steam-cooked mashed potatoes in water

Other: Dietary

Outcome Measures

Primary Outcome Measures

Plasma glucose concentration [0min, 20min, 40min, 60min, 90min, 120min, 180min, 240min]
Plasma insulin concentration [0min, 20min, 40min, 60min, 90min, 120min, 180min, 240min]

Secondary Outcome Measures

Concentrations and quality of metabolites and flavonoid color compounds and their metabolites in plasma (NMR and (U)HPLC-MS/MS measurements) [0min, 20min, 40min, 60min, 90min, 120min, 180min, 240min]
Concentrations and quality of metabolites and flavonoid color compounds and their metabolites in urine (NMR and (U)HPLC-MS/MS measurements) [Before meal, and 0-4h, 4-8h, 8-16h, 16-24 h]
Concentrations and quality of metabolites and flavonoid color compounds and their metabolites in feces (NMR and (U)HPLC-MS/MS measurements) [before and after meal]
Area under the glucose concentration curve (AUC) [0min, 20min, 40min, 60min, 90min, 120min, 180min, 240min]
Area under the insulin concentration curve (AUC) [0min, 20min, 40min, 60min, 90min, 120min, 180min, 240min]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 45 Years

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Age 18-45
Male
No regular medication
No participation in a drug trial or blood donation within 2 months
Non-smoker
Signs informed consent
Body mass index 18.5-27 kg/m2
Fasting plasma cholesterol < 5.5 mmol/l
Fasting plasma triacylglycerols < 2.6 mmol/l
Fasting plasma glucose 4-6 mmol/l
blood pressure <140/80 mmHg
hemoglobin>130 g/l
Fasting plasma alanine amino transferase (ALAT) <60 U/l (normal liver function)
Fasting plasma thyroid-stimulating hormone (TSH) 0.4 - 4.5 mU/l (normal thyroid function)
Fasting plasma creatinine <118 µmol/l (normal kidney function)

Exclusion Criteria:

Regular smoking
Alcohol abuse
Regular medication

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Department of Biochemistry, University of Turku	Turku		Finland	20014

Sponsors and Collaborators

University of Turku

Investigators

Principal Investigator: Kaisa M Linderborg, PhD, Department of Biochemistry, University of Turku

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Kaisa Linderborg, Principal Investigator, University of Turku

ClinicalTrials.gov Identifier:

NCT02940080

Other Study ID Numbers:

Siniset perunat 2

First Posted:

Oct 20, 2016

Last Update Posted:

Mar 14, 2022

Last Verified:

Mar 1, 2022

Study Results

No Results Posted as of Mar 14, 2022